RecruitingNCT07107932
A Registry： Siltartoxatug Injection for Tetanus Prophylaxis Following Injury
Studying Tetanus
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Zhuhai Trinomab Pharmaceutical Co., Ltd.
- Intervention
- Siltartoxatug Injection (Brand name: Sintetol®)(drug)
- Enrollment
- 10000 enrolled
- Eligibility
- All sexes
- Timeline
- 2025 – 2029
Study locations (4)
- The Second Affiliated Hospital of Shantou University, Shantou, Guangdong, China
- Xiangyun County People's Hospital, Xiangyun, Yunnan, China
- Shaoxing Central Hospital, Shaoxing, Zhejiang, China
- Zhoushan Putuo District People's Hospital, Zhoushan, Zhejiang, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07107932 on ClinicalTrials.govOther trials for Tetanus
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONPHASE1NCT07149454Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Recombinant Human Anti-Tetanus Toxin Monoclonal Antibody InjectionLanzhou Institute of Biological Products Co., Ltd
- RECRUITINGPHASE3NCT06635798A Phase III Clinical Trail to Evaluate the Efficacy, Safety, Pharmacokinetics and Immunogenicity Characteristics of GR2001 InjectionGenrix (Shanghai) Biopharmaceutical Co., Ltd.